You're describing a chemical compound, but the name you provided isn't quite a standard chemical name. It's likely a more descriptive name used in a specific research context. To understand its importance, we need to break it down and make some assumptions:
**Breaking Down the Name:**
* **2-(4-chloro-3,5-dimethylphenoxy)-:** This indicates a **phenol** (a benzene ring with an -OH group) with the following modifications:
* **4-chloro:** A chlorine atom is attached to the 4th position of the benzene ring.
* **3,5-dimethyl:** Two methyl groups (CH3) are attached to the 3rd and 5th positions of the benzene ring.
* **-phenoxy:** This part indicates that the phenol is connected to another molecule through an oxygen atom (-O-).
* **N-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]acetamide:** This indicates an **acetamide** (a molecule containing an -NHCOCH3 group). It's attached to a phenyl ring (benzene ring) with the following modifications:
* **4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]:**
* This means a piperazine ring (a six-membered ring with two nitrogen atoms) is attached to the 4th position of the phenyl ring.
* The piperazine ring itself has a furanyl(oxo)methyl group attached to it:
* **2-furanyl(oxo)methyl:** A furan ring (a five-membered ring with an oxygen atom) with a carbonyl group (C=O) and a methylene group (CH2) attached.
**Possible Significance:**
Based on the structure, this compound likely has biological activity and is used in research for the following reasons:
* **Potential Drug Development:** The compound contains features commonly found in drugs, like the phenol and acetamide groups, which are known to interact with biological systems. The piperazine ring is often used to bind to receptors in the brain, making it a promising starting point for developing new drugs.
* **Medicinal Chemistry Studies:** Researchers may be studying this compound to investigate its biological effects, such as its ability to bind to specific proteins, its ability to cross cell membranes, or its potential therapeutic activity. This research could lead to the development of new drugs for treating various diseases.
* **Chemical Synthesis & Design:** The compound's structure might be used as a basis for designing new molecules with improved properties or activity.
**To provide a more precise answer, you would need to tell us:**
* **What is the source of this name?** Is it from a scientific paper, a patent, a chemical database, or other source?
* **What is the context of the research?** What are the researchers investigating?
Knowing this information would help us understand the specific importance of this particular compound in the research.
ID Source | ID |
---|---|
PubMed CID | 1255242 |
CHEMBL ID | 1363851 |
CHEBI ID | 105770 |
Synonym |
---|
HMS1601C09 |
AP-970/43336862 |
smr000201380 |
2-(4-chloro-3,5-dimethylphenoxy)-n-{4-[4-(2-furoyl)-1-piperazinyl]phenyl}acetamide |
MLS000582679 , |
STK172708 |
2-(4-chloro-3,5-dimethylphenoxy)-n-{4-[4-(furan-2-ylcarbonyl)piperazin-1-yl]phenyl}acetamide |
CHEBI:105770 |
AKOS000460859 |
MLS002548377 |
2-(4-chloro-3,5-dimethylphenoxy)-n-[4-[4-(furan-2-carbonyl)piperazin-1-yl]phenyl]acetamide |
HMS2471L10 |
CHEMBL1363851 |
cid_1255242 |
2-(4-chloro-3,5-dimethyl-phenoxy)-n-[4-[4-(2-furoyl)piperazino]phenyl]acetamide |
bdbm41090 |
2-(4-chloranyl-3,5-dimethyl-phenoxy)-n-[4-[4-(furan-2-ylcarbonyl)piperazin-1-yl]phenyl]ethanamide |
2-(4-chloro-3,5-dimethylphenoxy)-n-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]acetamide |
Q27183546 |
Class | Description |
---|---|
piperazines | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 63.0957 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
WRN | Homo sapiens (human) | Potency | 17.1580 | 0.1683 | 31.2583 | 100.0000 | AID651768; AID720497 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 1.4581 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
USP1 protein, partial | Homo sapiens (human) | Potency | 31.6228 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
TDP1 protein | Homo sapiens (human) | Potency | 9.7613 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 1.4125 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
Smad3 | Homo sapiens (human) | Potency | 0.6310 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
67.9K protein | Vaccinia virus | Potency | 10.7509 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 79.4328 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 5.4063 | 0.5406 | 17.6392 | 96.1227 | AID720503 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 112.2020 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 8.1995 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
DNA polymerase beta | Homo sapiens (human) | Potency | 6.3096 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
flap endonuclease 1 | Homo sapiens (human) | Potency | 89.1251 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 15.1014 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 82.1771 | 0.1000 | 28.9256 | 213.3130 | AID588591; AID720502 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 32.9110 | 0.0501 | 27.0736 | 89.1251 | AID588590; AID720496 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 0.2239 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
PTK2B protein tyrosine kinase 2 beta | Homo sapiens (human) | IC50 (µMol) | 5.9560 | 1.5370 | 4.0805 | 6.9220 | AID1641 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |